Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
- Associated Conditions
- -
- Associated Therapies
- -
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 319
- Registration Number
- NCT03996772
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
🇩🇪University Hospital Schleswig-Holstein Campus Luebeck, Luebeck, Germany
🇩🇪Klinikum Altenburger Land, Altenburg, Germany
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 620
- Registration Number
- NCT03961334
- Locations
- 🇬🇷
Attikon University Hospital, Athens, Greece
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇨🇭University Hospital of Basel, Basel, Switzerland
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- University of Rhode Island
- Target Recruit Count
- 40
- Registration Number
- NCT03752294
Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT03742336
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 1120
- Registration Number
- NCT03536611
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 1512
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
🇩🇪Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
🇩🇪Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1489
- Registration Number
- NCT03258645
- Locations
- 🇸🇪
SITS International (c/o Karolinska University Hospital), Stockholm, Sweden
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22490
- Registration Number
- NCT03254134
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.